Follow the latest company announcements, clinical research milestones, strategic developments, and updates from Adia Med.
Regenerative medicine peptides cover far more than the popular BPC-157 vs TB-500 debate. This 2026 matrix maps five major peptide classes, clarifying FDA approval, Category 2 delisting, and compounding eligibility amid a pivotal year of regulatory change.
Curious what stem cell therapy for hair regrowth can really deliver? This article breaks down clinical data on hair count and density gains across ADSC, SVF, and exosome treatments, plus a realistic month-by-month timeline for results.
The Alliance for Regenerative Medicine’s 2026 State of the Industry data offers a critical lens into cell and gene therapy’s growth, from five commercial blockbusters to a sharp rise in FDA Complete Response Letters. This article breaks down what ARM’s key metrics mean for investors, analysts, and anyone tracking the CGT pipeline.
This guide tackles therapist development for rehab clinicians navigating regenerative medicine in 2026. Learn the science behind mechanotransduction, scope-of-practice rules across the US and UK, and a practical roadmap for building clinical credibility.
Non-small cell lung cancer therapy is evolving beyond chemotherapy and radiation into a biomarker-driven, personalized approach. This guide breaks down NSCLC treatment by actionable mutation and explores how CAR-T, TIL therapy, and mRNA vaccines are reshaping the future of care in 2026.
Navigating cutaneous T-cell lymphoma therapy can be confusing when resources focus on drug classes instead of patient stages. This 2026 guide organizes treatment options around three real-world pathways: newly diagnosed skin-limited MF, blood-involved disease like Sézary syndrome, and relapsed or refractory CTCL, with clear signs for when to escalate care.
Correctly classifying software for medical devices determines every downstream compliance decision, from FDA pathway to IEC 62304 safety class. This 2026 guide offers a classification-first framework covering SaMD, SiMD, and CDS, plus key regulatory shifts including FDA’s new QMSR and cybersecurity guidance.
Discover how regenerative medicine NJ blends cutting-edge Rutgers Health research with real-world orthobiologic clinics across the state. This guide breaks down PRP, stem cell therapies, and a safety-first framework to help patients choose a trustworthy provider.
Navigating medical devices FDA regulation in 2026 means understanding more than the classic 510(k), De Novo, and PMA pathways. This guide uses FDA’s own 2026 data, covering the QMSR overhaul, cybersecurity mandates, and the AI-enabled device surge, to explain how approval really works today. It’s built for patients, clinicians, manufacturers, and investors alike.
Discover 12 real, verifiable regenerative medicine examples spanning stem cell therapies, PRP, tissue engineering, and gene therapy. Each case is clearly labeled FDA-approved, RMAT-designated, or investigational so you know exactly where the science stands in 2026.
Not all hair loss cases fit the same stem cell treatment advice. This guide breaks down FDA-approved options, pipeline trials, and unproven clinic offerings by hair loss stage so you know exactly where you stand in 2026.
Stem cell baldness treatment candidacy isn’t a simple yes-or-no answer—it’s a five-stage spectrum shaped by dormant vs. destroyed follicles. Learn where you fit, what 2026 research reveals, and what’s actually available today.
TAKE THE NEXT STEP
Consultations are confidential and conducted by our Orlando-based
clinical staff - for local and international patients alike.
